
|Articles|July 1, 2002
Intravitreal triamcinolone for AMD appears promising, but more studies needed
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Intravitreal triamcinolone appears to inhibit the growth of choroidal neovascularization (CNV) and reduce subretinal fluid in the short term, but it needs further evaluation, ac-cording to Mark Gillies, MB, BS, PhD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ)
2
Self-Screening for Ocular Surface Malignancies Using a Smartphone
3
Closing the gap: John Berdahl, MD, on the global cataract burden and the emerging dementia connection
4
Durability and Unmet Needs in Retinal Vascular Diseases
5





















